EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Visualized Clinical‐Radiomics Model Based on Non‐Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms

Miaomiao Feng iD, Man Zhao, Xiaoling Duan, Jiaojiao Hou, Qi Wang, Fei Yin iD

Cancer Medicine · 2026-05 · 15 (5)

DOI: 10.1002/cam4.71931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 12.05.2026. Verfasst von Miaomiao Feng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Neuroendocrine Tumors, Tomography, X-Ray Computed, Phenylurea Compounds. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Application of Artificial Intelligence-Based Chest Non-Contrast CT Imaging Analysis in the Diagnosis of Early Esophageal Cancer, Wu Jieping Medical Foundation Scientific Research Special Grant Project, S&T Program of Hebei, the Key Research and Development Plan Program of Hebei, the Health Innovation Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatic metastatic neuroendocrine neoplasms (HM‐NENs) have few treatment biomarkers and low survival rates. We created a clinical‐radiomics fusion model based on non‐contrast computed tomography (NCCT) to predict Surufatinib efficacy in HM‐NENs. We presented it as a nomogram, meeting unmet requirements in precision medicine.

Methods

This retrospective study included 76 HM‐NEN patients (131 hepatic metastases) treated with Surufatinib. Regions of interest (ROI) were manually segmented, and the best response to Surufatinib was decided based on Modified Response Evaluation Criteria in Solid Tumor (mRECIST). Radiomics features were extracted from the pretreatment NCCT. The Least Absolute Shrinkage and Selection Operator (LASSO) was used to select radiomics features and calculate a Radiomics score (Radscore). Multivariable logistic regression analysis was utilized to create the clinical‐radiomics fusion model, which included clinical characteristics and Radscore and was displayed as a nomogram. The area under the receiver operating characteristic curve (ROC) was used to assess model performance, and internal validation was done using the bootstrap resampling approach.

Results

After multivariate logistic regression analysis, the Radscore, the diameter of hepatic metastasis, the number of hepatic metastases, and extrahepatic metastasis were included as predictors in the final model. The area under the curve (AUC) of the clinical‐radiomics fusion model to predict the response of Surufatinib of HM‐NENs was 0.926 (95% confidence interval [CI]: 0.881–0.971). The AUC verified by bootstrap was 0.926 (95% CI: 0.880–0.966), indicating a good performance of the fusion model.

Conclusion

The clinical‐radiomics fusion model can effectively identify patients with HM‐NENs sensitive to Surufatinib therapy. The nomogram provides clinicians with a convenient and dependable tool for decision‐making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsNeuroendocrine TumorsTomography, X-Ray ComputedPhenylurea CompoundsHumansFemaleRadiomicsRetrospective StudiesMaleMiddle AgedAgedNomogramsAdultTreatment Outcome

Stichwörter der Autor:innen

clinical‐radiomics modelefficacyhepatic metastatic neuroendocrine neoplasmsnon‐contrast computed tomographysurufatinib

Substanzen

Phenylurea Compounds

Autor:innen und Institutionen

  • Department of Gastroenterology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of CT and MRI, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.

ORCID-Profile: Miaomiao Feng, Fei Yin

Förderung

  • Application of Artificial Intelligence-Based Chest Non-Contrast CT Imaging Analysis in the Diagnosis of Early Esophageal Cancer
  • Wu Jieping Medical Foundation Scientific Research Special Grant Project
  • S&T Program of Hebei, the Key Research and Development Plan Program of Hebei, the Health Innovation Program
  • Local Science and Technology Development Fund of Hebei Province

Zitieren

APA

Feng, M., Zhao, M., Duan, X., Hou, J., Wang, Q., & Yin, F. (2026). Visualized Clinical‐Radiomics Model Based on Non‐Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71931

Vancouver

Feng M, Zhao M, Duan X, Hou J, Wang Q, Yin F. Visualized Clinical‐Radiomics Model Based on Non‐Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71931

BibTeX
@article{Feng2026,
  author = {Feng, Miaomiao and Zhao, Man and Duan, Xiaoling and Hou, Jiaojiao and Wang, Qi and Yin, Fei},
  title = {Visualized Clinical‐Radiomics Model Based on Non‐Contrast Computed Tomography for Predicting Efficacy of Surufatinib in Hepatic Metastases of Neuroendocrine Neoplasms},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.1002/cam4.71931}
}
Kostenlos starten →